Pharmaceutical Pricing and Medical Innovation
Other featured articles
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Without Reform, Medicare Policies Will Hamstring New Gene Therapies
It took until the fall of 2020 for Medicare to consistently pay an adequate amount for CAR-T therapy. Now that same agonizing process awaits a raft of promising gene therapies in the pipeline – with lives in the balance – unless policymakers take action.
USC Schaeffer Center and Aspen Institute Advisory Panel Recommend Ways to Modernize Health Technology Assessment in the U.S.
The U.S. has no public organization dedicated to producing and evaluating HTAs despite the potential of HTAs providing critical input about price and value, while also recognizing the contribution of innovation to advancing health and healthcare.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.